Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trialGe Tao, Peng Zhang, Xinsheng Zhu et al.|EClinicalMedicine|2025Cited by 0